Insider Selling: uniQure (NASDAQ:QURE) Director Sells 1,993 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director David Meek sold 1,993 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the sale, the director owned 39,747 shares in the company, valued at approximately $1,075,553.82. The trade was a 4.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

uniQure Trading Up 2.8%

QURE stock traded up $0.75 during midday trading on Friday, reaching $27.57. The company’s stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock has a fifty day simple moving average of $22.31 and a two-hundred day simple moving average of $21.76. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. On average, equities research analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in QURE. State Street Corp boosted its position in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. boosted its position in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC boosted its position in uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new stake in uniQure during the fourth quarter valued at about $33,062,000. Institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $11.00 to $35.00 in a research report on Monday, March 9th. Stifel Nicolaus set a $28.00 price target on uniQure in a research report on Tuesday, May 5th. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. Finally, Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.